Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933161 | 0.95 | KDM1A (0.44) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL29404068 | 0.95 | KDM1A (0.44) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL22917359 | 0.95 | KDM1A (0.44) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL932672 | 0.95 | KDM1A (0.44) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL15017144 | 0.93 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL15017843 | 0.93 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL29526160 | 0.93 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| Hydrochloric Acid SCHEMBL15017147 | 0.93 | KDM1A (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL28286568 | 0.92 | KCNH2 (0.43) | KDM1AKDM1BMEN1KMT2AKCNH2 | |
| SCHEMBL1765144 | 0.86 | MEN1 (0.42) | MEN1KMT2ACYP2D6CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782391-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| US-9782391-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| US-9782391-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2017-10-10 | — | — | US | disclosed |
| EP-3157921-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | Dr. Reddy's Laboratories Ltd. (IN) | 2017-04-26 | — | — | EP | disclosed |
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-09-29 | — | — | US | disclosed |
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-09-29 | — | — | US | disclosed |
| US-9394305-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-9394305-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| US-9394305-B2 | Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-07-19 | — | — | US | disclosed |
| WO-2015200341-A1 | SUBSTITUTED IMIDAZO[1,2-A]PYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-30 | — | — | WO | disclosed |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-24 | — | — | US | disclosed |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-24 | — | — | US | disclosed |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-12-24 | — | — | US | disclosed |
| CN-102753538-B | Sultam derivatives | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2504324-A1 | SULTAM DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279109-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | KDM1A 2189/4885KDM1B 3679/4885MEN1 3912/4885 |
| US-20150368238-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS | NTRK1, NTRK3, MUSK | KDM1A 2189/4885KDM1B 3679/4885MEN1 3912/4885 |
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | KDM1A 1432/4885KDM1B 1866/4885MEN1 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.